Back to News
Market Impact: 0.32
Tuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade
Source: youtube.com
Healthcare & BiotechCompany Fundamentals
Amgen shares sold off after Novartis failed to meet the primary endpoint in a Phase 3 clinical trial. The trial setback triggered volatile trading across healthcare-related stocks, though the article provides no trial data, financial magnitude, or direct explanation of Amgen's exposure.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
AMGN-0.35
NVS-0.80
More News
- Cholesterol drug setback casts doubt over multibillion-dollar race
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
- Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
- Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries